FISCAL NOTE

Date Requested: January 14, 2023
Time Requested: 03:44 PM
Agency: Insurance Commission
CBD Number: Version: Bill Number: Resolution Number:
1313 Introduced HB2430
CBD Subject:


FUND(S):

7152 OIC Operating Fund

Sources of Revenue:

Special Fund

Legislation creates:





Fiscal Note Summary


Effect this measure will have on costs and revenues of state government.


The purpose of House Bill 2430 is to reduce the copay cap on insulin and devices for diabetics. House Bill 2430, if enacted, would have no fiscal impact on the Offices of the Insurance Commissioner. Please see the memorandum section of this fiscal note for additional information.



Fiscal Note Detail


Effect of Proposal Fiscal Year
2023
Increase/Decrease
(use"-")
2024
Increase/Decrease
(use"-")
Fiscal Year
(Upon Full
Implementation)
1. Estmated Total Cost 0 0 0
Personal Services 0 0 0
Current Expenses 0 0 0
Repairs and Alterations 0 0 0
Assets 0 0 0
Other 0 0 0
2. Estimated Total Revenues 0 0 0


Explanation of above estimates (including long-range effect):






Memorandum


House Bill 2430, if enacted, would reduce the copay cap on insulin and devices for diabetics. House Bill 2430 would have no fiscal impact on the operations, expenses or revenues of the Offices of the Insurance Commissioner. PEIA should be consulted regarding the fiscal impact to their agency. It should be noted that HB2430 does not contain language limiting the insurance benefits provided under the bill to the essential health benefits (EHB) specified under section 130(b) of the Patient Protection and Affordable Care Act (PPACA). PPACA 1311(d)(3) provides that a state must defray the cost by direct payment to the enrollees or to the Plan of any state mandated benefit in excess of the EHB. To the extent that the health insurance benefits required by HB2430 do not fall within the EHB, a potential cost to the State exists.



    Person submitting Fiscal Note: Rhonda Hartwell
    Email Address: rhonda.c.hartwell@wv.gov